LWM
ALNY icon

LeConte Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

LeConte Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$228K Buy
759
+64
+9% +$19.3K 0.12% 140
2026
Q1 		$230K Buy
695
+91
+15% +$31K 0.15% 123
2025
Q4 		$240K Buy
604
+78
+15% +$34.5K 0.16% 106
2025
Q3 		$240K Buy
+526
New +$214K 0.16% 101

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

LeConte Wealth Management's ALNY Position: Q2 2026 in Review

LeConte Wealth Management increased its Alnylam Pharmaceuticals (ALNY) stake by 9.2% in Q2 2026, buying an estimated $19.3K and bringing the position to 759 shares worth $228K. The position accounts for 0.12% of the portfolio, ranked #140.

LeConte Wealth Management first reported a position in ALNY in Q3 2025 and has held it in 4 quarters since. The position peaked at $240K in Q4 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • LeConte Wealth Management held 759 shares of Alnylam Pharmaceuticals worth $228K as of Q2 2026.
  • LeConte Wealth Management bought 64 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $19.3K.
  • Alnylam Pharmaceuticals made up 0.12% of LeConte Wealth Management's portfolio in Q2 2026, its #140 holding.
  • LeConte Wealth Management first reported a position in Alnylam Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • LeConte Wealth Management's Alnylam Pharmaceuticals position peaked at $240K in Q4 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on LeConte Wealth Management's 13F filing for Q2 2026, filed 7 Aug 2026.